Status:
UNKNOWN
Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis
Lead Sponsor:
Xijing Hospital
Conditions:
Bullous Pemphigoid
Eligibility:
All Genders
Up to 100 years
Brief Summary
Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity. Various inflammatory cells such as e...
Eligibility Criteria
Inclusion
- (1) Patients with Bullous Pemphigoid who were first hospitalized in the Department of Dermatology of Xijing Hospital
- (2) Age 0-100 years old, gender is not limited.
- (3) Diagnosis is confirmed by clinical, histopathologic, immunopathologic and/or anti-BP180 antibody tests.
- (4) Complete skin histopathology information
Exclusion
- (1) Patients with Bullous Pemphigoid who were not first diagnosed in our hospital.
- (2) Those who have received systemic glucocorticoid, immunosuppressant, biologic, or other drug therapy within the past month.
Key Trial Info
Start Date :
January 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2024
Estimated Enrollment :
318 Patients enrolled
Trial Details
Trial ID
NCT06213909
Start Date
January 11 2024
End Date
June 30 2024
Last Update
January 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xijing Hospital
Xi'an, Shaanxi, China, 710032